Roche sales surpass Novartis'

Roche

Eat dust, Novartis. Roche just posted sales of $42.2 billion, $2.4 billion more than its Swiss rival's $39.8 billion. Strong sales of its cancer drugs helped boost profits by 25 percent to $10.48 billion. The rheumatoid arthritis and lymphoma treatment Rituxan alone delivered revenues of $5 billion, becoming the company's best-selling drug ahead of cancer meds Herceptin and Avastin.

The outlook for 2008 isn't all rosy, however. Tamiflu sales, which dropped 19 percent to $1.9 billion in 2007, will continue to fall off, and Herceptin growth is expected to slow, too. Overall, sales growth will drop to the single digits--and this after seven consecutive years of double-digit increases.

It's flush with cash, though, which it plans to use to accelerate R&D spending and to acquire small to medium-sized companies; it's looking primarily in the diagnostics area, but also would consider small pharma deals. Mega-mergers, however, aren't in the cards, CEO Franz Humer said. Of course, Roche has its Ventana deal to wrap up by the second half of 2008.

INDUSTRY RESEARCH

Veeva 2019 Unified Clinical Operations Survey

Share your thoughts in this quick survey. The first 50 qualified respondents will receive a $5 Amazon gift card, and, in appreciation for your time, all qualified survey respondents will be entered in a drawing to win a $50 Amazon gift card.

- see the release from Roche
- read the article in the Financial Times
 

Read more on